<DOC>
	<DOCNO>NCT00004195</DOCNO>
	<brief_summary>RATIONALE : Eniluracil may increase effectiveness chemotherapy block tumor enzyme break chemotherapy drug . PURPOSE : Randomized phase II trial determine effectiveness eniluracil follow surgery treating patient primary metastatic colorectal cancer .</brief_summary>
	<brief_title>Eniluracil Surgery Treating Patients With Primary Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine enzymatic activity dihydropyrimidine dehydrogenase ( DPD ) peripheral blood mononuclear cell ( PBMC ) , normal mucosa , normal liver patient primary metastatic colorectal cancer . II . Evaluate ability eniluracil inactivate DPD tumor , PBMCs , normal tissue patient population . III . Assess DPD recovery uracil level PBMCs follow surgical resection patient . OUTLINE : This randomize , placebo control study . Patients stratify accord colorectal tumor ( primary v metastatic ) . Patients randomize one two treatment arm . Arm I : Patients receive oral eniluracil twice daily day -2 -1 follow surgical resection tissue harvest day 0 . Arm II : Patients receive oral placebo arm I follow surgical resection tissue harvest day 0 . Patients follow weekly 1 month . PROJECTED ACCRUAL : A total 20 patient ( 10 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>Inclusion : 1 . DISEASE CHARACTERISTICS : Histologically proven suspicious primary metastatic colorectal carcinoma undergoing disease resection 2 . PATIENT CHARACTERISTICS : A . Age : 19 3 . Performance status : Karnofsky 60100 % 4 . Not pregnant nursing Fertile patient must use effective contraception least 1 month study 5 . PRIOR CONCURRENT THERAPY : 6 . Subject least 8 week since prior fluorouracil , capecitabine , fluorouraciluracil , floxuridine , S1 Endocrine therapy : 7 . No prior concurrent steroid Radiotherapy : 8 . Surgery : No prior emergent surgery ( e.g. , perforation obstruction ) No prior transplantation 9 . At least 8 week since prior drug metabolize dihydropyrimidine dehydrogenase enzyme At least 8 week since prior flucytosine Exclusion : 1 . Severe infection ( White Blood Cell Count ) WBC &gt; 2 time normal 2 . Fever 3 . Sepsis 4 . Subject immunosuppressives therapy 5 . Subjects serum Bilirubin/Creatinine &gt; 2 time normal level 6 . Pregnant /Lactating woman 7 . Subjects receive eniluracil 5FU ( Fluorouracil ) within 28 day prior randomization 8 . Subject comorbidity illnesses increase likelihood death &lt; 5 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>